246 related articles for article (PubMed ID: 29468487)
21. 18 F-MFBG PET/CT Is an Effective Alternative of 68 Ga-DOTATATE PET/CT in the Evaluation of Metastatic Pheochromocytoma and Paraganglioma.
Wang P; Li T; Cui Y; Zhuang H; Li F; Tong A; Jing H
Clin Nucl Med; 2023 Jan; 48(1):43-48. PubMed ID: 36252940
[TBL] [Abstract][Full Text] [Related]
22. Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma: a pilot study.
Almeida LS; Araújo MC; Zantut-Wittmann DE; Assumpção LV; Souza TF; Silva CM; Argenton JL; Santos AO; Mengatti J; Ramos CD; Etchebehere EC
Nucl Med Commun; 2018 May; 39(5):441-450. PubMed ID: 29543624
[TBL] [Abstract][Full Text] [Related]
23. Complete Response to 177 Lu-DOTATATE PRRT in a 9-Year-Old Child With Metastatic Carotid Body Paraganglioma.
Yadav MP; Raju S; Ballal S; Bal C
Clin Nucl Med; 2024 Jan; 49(1):e33-e34. PubMed ID: 37976428
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.
Maurice JB; Troke R; Win Z; Ramachandran R; Al-Nahhas A; Naji M; Dhillo W; Meeran K; Goldstone AP; Martin NM; Todd JF; Palazzo F; Tan T
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1266-70. PubMed ID: 22526961
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact of
Tuncel M; Kılıçkap S; Süslü N
Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032
[TBL] [Abstract][Full Text] [Related]
26. Multiple endocrine neoplasia type 2A syndrome (MEN2A) and usefulness of 68Ga-DOTATATE PET/CT in this syndrome.
Tuzcu SA; Pekkolay Z
Ann Ital Chir; 2019; 90():497-503. PubMed ID: 30837349
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
28. Comparison of 18 F-MFBG and 68 Ga-DOTATATE PET/CT in the Imaging of Metastatic Paraganglioma and Pheochromocytoma.
Deng M; Shu Q; Hu M; Chen Y; Cai L
Clin Nucl Med; 2022 Dec; 47(12):e735-e737. PubMed ID: 35777982
[TBL] [Abstract][Full Text] [Related]
29. Bone Metastasis of Glomus Caroticum Demonstrated on 68 Ga-DOTATATE PET/CT.
Kesim S; Sen F; Filizoglu N; Ozguven S; Erdil TY
Clin Nucl Med; 2022 Nov; 47(11):e706-e707. PubMed ID: 35867988
[TBL] [Abstract][Full Text] [Related]
30. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
31. Reduced uptake pattern on
de Jong MC; Pinto D; Parameswaran R
J Surg Oncol; 2023 Oct; 128(5):764-768. PubMed ID: 37403579
[TBL] [Abstract][Full Text] [Related]
32. Integrated PET/MRI With 68Ga-DOTATATE and 18F-FDG in Pheochromocytomas and Paragangliomas: An Initial Study.
Xu S; Pan Y; Zhou J; Ju H; Zhang Y
Clin Nucl Med; 2022 Apr; 47(4):299-304. PubMed ID: 35143455
[TBL] [Abstract][Full Text] [Related]
33. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
34. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
[TBL] [Abstract][Full Text] [Related]
35. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.
Fendler WP; Barrio M; Spick C; Allen-Auerbach M; Ambrosini V; Benz M; Bluemel C; Grewal RK; Lapa C; Miederer M; Nicolas G; Schuster T; Czernin J; Herrmann K
J Nucl Med; 2017 Feb; 58(2):307-311. PubMed ID: 27539839
[TBL] [Abstract][Full Text] [Related]
36. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
37. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients.
Cleary JO; Yeung J; McMeekin H; Wilhelm T; Wagner T
Nucl Med Commun; 2016 Nov; 37(11):1197-205. PubMed ID: 27399848
[TBL] [Abstract][Full Text] [Related]
38. 68 Ga-DOTATATE PET to Characterize Lesions in the Neuroaxis.
Hartmann K; Gillman JA; Lazor JW; Ware JB; Weeks JK; Nasrallah IM; Farwell MD; Pantel AR
Clin Nucl Med; 2024 Jan; 49(1):9-15. PubMed ID: 38048554
[TBL] [Abstract][Full Text] [Related]
39. (68)Ga-DOTATATE PET/CT imaging in carotid body tumor.
Gayana S; Mittal BR; Bhattacharya A; Radotra BD; Gupta AK
Clin Nucl Med; 2013 Apr; 38(4):e191-3. PubMed ID: 23455532
[TBL] [Abstract][Full Text] [Related]
40. Value of the
Fastrez M; Artigas C; Sirtaine N; Wimana Z; Caillet M; Rozenberg S; Flamen P
Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():69-74. PubMed ID: 28342392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]